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ABSTRACT
The Zn-dependent membrane-located protease YvjB has previously been shown to serve as a target receptor for LsbB, a class II
leaderless lactococcal bacteriocin. Although yvjB is highly conserved in the genus Lactococcus, the bacteriocin appears to be ac-
tive only against the subspecies L. lactis subsp. lactis. Comparative analysis of the YvjB proteins of a sensitive strain (YvjBMN)
and a resistant strain (YvjBMG) showed that they differ from each other in 31 positions. In this study, we applied site-directed
mutagenesis and performed directed binding studies to provide biochemical evidence that LsbB interacts with the third trans-
membrane helix of YvjB in susceptible cells. The site-directed mutagenesis of LsbB and YvjB proteins showed that certain amino
acids and the length of LsbB are responsible for the bacteriocin activity, most probably through adequate interaction of these
two proteins; the essential amino acids in LsbB responsible for the activity are tryptophan (Trp25) and terminal alanine (Ala30). It
was also shown that the distance between Trp25 and terminal alanine is crucial for LsbB activity. The crucial region in YvjB for
the interaction with LsbB is the beginning of the third transmembrane helix, particularly amino acids tyrosine (Tyr356) and ala-
nine (Ala353). In vitro experiments showed that LsbB could interact with both YvjBMN and YvjBMG, but the strength of interac-
tion is significantly less with YvjBMG. In vivo experiments with immunofluorescently labeled antibody demonstrated that LsbB
specifically interacts only with cells carrying YvjBMN.
IMPORTANCE
The antimicrobial activity of LsbB bacteriocin depends on the correct interaction with the corresponding receptor in the bacte-
rial membrane of sensitive cells. Membrane-located bacteriocin receptors have essential primary functions, such as cell wall syn-
thesis or sugar transport, and it seems that interaction with bacteriocins is suicidal for cells. This study showed that the C-termi-
nal part of LsbB is crucial for the bacteriocin activity, most probably through adequate interaction with the third
transmembrane domain of the YvjB receptor. The conserved Tyr356 and Ala353 residues of YvjB are essential for the function of
this Zn-dependent membrane-located protease as a bacteriocin receptor.
Bacteriocins are small, ribosomally synthesized, cationic, andhydrophobic peptides produced by various bacteria, and they
are often found to be active against bacteria closely related to the
producers. However, some also have broader inhibitory spectra,
including pathogens and problematic bacteria. Producer organ-
isms are immune to their own bacteriocin(s), a property that is
mediated by specific immunity proteins (1).
Bacteriocins from Gram-positive bacteria are generally classi-
fied into two main groups: the class I lantibiotics, containing post-
translationally modified peptides with ring-forming lanthionine
or methyllanthionine residues, and class II, composed of non-
modified or minimally modified peptide bacteriocins (1–3). Class
II bacteriocins are further subdivided into pediocin-like bacterio-
cins (class IIa), two-peptide bacteriocins (class IIb), circular bac-
teriocins (class IIc), and nonpediocin one-peptide bacteriocins
(class IId) (2).
Bacteriocins have been much studied from a fundamental and
scientific perspective and also for their potential applications as
food preservatives, and in veterinary and human medicine as al-
ternatives to antibiotics or as synergists (1, 4).
Bacteriocins have a number of positive attributes that have
made them especially attractive for various applications (5). Some
of them exhibit a broad spectrum of activity, inhibiting microor-
ganisms belonging to different genera and species, including
many bacterial pathogens that cause human, animal, or plant in-
fections (6). For clinical applications, bacteriocins have been pre-
sented as a viable alternative to antibiotics due to the high speci-
ficity of certain bacteriocins against clinical pathogens, including
multidrug-resistant (MDR) strains (4). Therefore, these sub-
stances have various potential applications in the food industry
and medicine, either alone or in combination with other chemi-
cals or methods (7).
The multiplicity and diversity of bacteriocins and the resultant
effects of their interactions with targeted bacteria on microbial
ecology have been thoroughly studied and remain an area of in-
vestigation, attracting many researchers (8).
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The mechanisms involved in the inhibitory activity of bacte-
riocins produced by Gram-positive bacteria toward target cells
have been shown to be diverse. Lipid II, along with related cell wall
precursors, has been identified as both the receptor and the target
for several class I bacteriocins from the lantibiotic subgroup (9–
11), as well as for the class II bacteriocin lactococcin 972 (12). The
mannose phosphotransferase system (man-PTS) has been found
to be involved in the sensitivity to some bacteriocins, but it was not
until 2007 that it was finally established that man-PTS serves as a
receptor for the class IIa (i.e., pediocin-like) and some class IId
bacteriocins (lactococcin A and lactococcin B) (13, 14). In recent
years, several other receptors have been identified through a ge-
nome sequencing approach. A maltose-ABC transporter was
found to be required in target cells for sensitivity to garvicin ML, a
circular bacteriocin (class IIc) (15). By screening of a cosmid li-
brary and genome sequencing of resistant mutants, a Zn-depen-
dent metallopeptidase was found to be the target for the LsbB
(class IId) and related bacteriocins (16). In addition, UppP has
been found to be the bacteriocin receptor for lactococcin G and
enterocin 1071 (both class IIb) (17). Although all these bacterio-
cins differ greatly from each other in many aspects, including
physicochemical properties, composition, target specificity, width
of spectrum, and mode of action, they all share a feature, which is
the fact that they all target components of the bacterial membrane.
LsbB is a 30-amino-acid (aa) leaderless class IId bacteriocin
produced by Lactococcus lactis subsp. lactis BGMN1-5 (18). It has
a narrow inhibitory spectrum containing mostly lactococcal
strains. The target receptor for LsbB is YvjB, a member of the
highly conserved Zn-dependent membrane-located protease M50
protein family (16). Some members of this protein family are
known to be involved in gene regulation in response to stress in
Escherichia coli and Enterococcus faecalis (19–22). However, the
role of YvjB in Lactococcus is presently unknown. It seems that
LsbB interacts with YvjB with its C-terminal part (23). In this
study, we further analyzed the residues of LsbB and its membrane
receptor YvjB that are essential for their interaction.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The strains, their
derivatives, and plasmids used in this study are listed in Table 1. Lacto-
coccal and enterococcal strains were grown in M17 medium (Merck
GmbH, Darmstadt, Germany) supplemented with D-glucose (0.5% [wt/
vol]) (GM17) at 30°C. Escherichia coli DH5, TOP10, M15, and
BL21(DE3) were used for cloning and propagation of constructs and were
grown in Luria-Bertani (LB) broth aerobically at 37°C. To each medium,
agar (1.5% [wt/vol]; Torlak, Belgrade, Serbia) was added for use as a solid
medium. Transformants of lactococci and enterococci were selected on
GM17 plates containing 10 g/ml erythromycin (Sigma-Aldrich Chemie
GmbH, Deisenhofen, Germany) or 7.5 g/ml chloramphenicol (final
concentration). E. coli transformants were selected on LB plates contain-
ing 300 g/ml erythromycin, 100 g/ml ampicillin, or 100 g/ml kana-
mycin, depending on the plasmids used. When necessary, 5-bromo-4-
chloro-3-indolyl-D-galactoside (X-gal) (Fermentas, Vilnius, Lithuania)
was added to LB or GM17 medium plates at a final concentration of 50
g/ml, for blue/white screening of colonies carrying vectors with clones.
Test for bacteriocin activity. For detection of bacteriocin activity of
lactococci, recombinant strains, and mutants, an agar well diffusion assay
was performed as described previously by Kojic et al. (24). To test the level
of LsbB production, zones of inhibition were compared by size and inten-
sity with zones formed by synthetic LsbB (known concentrations) and two
control strains, L. lactis BGMN1-596T and MG7284 carrying pAZILlsbB,
in order to quantify production by different producers.
DNA manipulations. Electrocompetent L. lactis subsp. cremoris
MG7284 and Enterococcus faecalis BGZLS10-27 cells were prepared as
described by Holo and Nes (25). Transformations were done by electro-
poration using an Eppendorf electroporator (Eppendorf, Hamburg, Ger-
many), except E. coli DH5, EC101, TOP10, M15, and BL21, which were
transformed by heat shock. Appropriate agar plates with antibiotics were
used for the selection of transformants.
Plasmid DNA from E. coli DH5, EC101, TOP10, M15, and BL21 was
isolated using the QIAprep Spin miniprep kit (Qiagen GmBH, Hilden,
Germany). Digestion with restriction enzymes was conducted according
to the supplier’s instructions (Fermentas). DNA fragments were purified
from agarose gels using a QIAquick gel extraction kit, as described by the
manufacturer (Qiagen).
DNA was ligated with T4 DNA ligase (Agilent Technologies, USA),
according to the manufacturer’s recommendations.
The sets of specific primers used in this study are listed in Table 2. Kapa
Taq DNA polymerase (Kapa Biosystems, Inc., Boston, MA, USA) was
used to amplify DNA fragments by PCR using a GeneAmp PCR system
2700 thermal cycler (Applied Biosystems, Foster City, CA, USA). PCR
products were purified with a QIAquick PCR purification kit (Qiagen),
according to the protocol of the supplier, and sequenced by the Macrogen
Sequencing Service (Macrogen, The Netherlands). The DNA Strider pro-
gram was used for open reading frame (ORF) prediction. Commercial
pGEM-T-Easy (Promega, Madison, WI, USA) or laboratory vector
pBS-TA (26) was used for cloning of PCR products.
-Galactosidase activity assay. Membrane damage of lactococcal
cells caused by LsbB was determined using a modified -galactosidase
assay described by O’Neill and coauthors (27). The activity of -galacto-
sidase was determined from the logarithmic phase of MG7284, BGMN1-
596, and BGMN1-596R2/23 (16) carrying pNZ8150lacZ1PlcnB (28) by
assaying the degradation of ortho-nitrophenyl--galactoside (ONPG)
(Sigma-Aldrich Co., St. Louis, MO) at 30°C using a modified method
described by Miller (29). Cells from 1 ml of logarithmic-phase (optical
density at 600 nm [OD600], 0.6) cultures were collected by centrifuga-
tion, resuspended in 500 l of PP buffer (0.5 M sucrose, 40 mM NH4-
acetate, 10 mM Mg-acetate [pH 7]) containing 4 mg/ml lysozyme, and
incubated 30 min at 37°C. Protoplasts were harvested by centrifugation
(1,500  g) and resuspended in 200 l of TE buffer (10 mM Tris-HCl, 1
mM EDTA [pH 8.0]). Suspensions were divided into two parts of 100 l
and to each was added 500 l of Z buffer (60 mM Na2HPO4·7H2O, 40 mM
NaH2PO4·H2O, 10 mM KCl, 1 mM MgSO4·7H2O, 50 mM -mercapto-
ethanol). To one mixture, 20 l of chloroform and 20 l of 0.1% SDS were
added, and to a second mixture, LsbB (100 g/ml) was added. These
mixtures were incubated for 10 min at room temperature (RT) before
centrifuging at 16,000  g for 3 min to pellet undisrupted protoplasts. The
supernatants were transferred to new tubes, and 200 l of ONPG (4 mg/
ml) was added. After the appearance of yellow color, the reactions were
stopped by adding 250 l of 1 M Na2CO3, and A420 values were measured
for the supernatants. -Galactosidase activity in Miller units was calcu-
lated as 1,000  A420/(t  v  OD600), where t is time in minutes, v is the
volume of culture used in the assay in milliliters, and OD600 is the optical
density of the culture at 600 nm. The efficiency of membrane damage
caused by LsbB was calculated as the percentage of -galactosidase activity
obtained by treatment of cells with LsbB (100 g/ml) compared to those
obtained by SDS and chloroform (activity obtained by treatment with
SDS and chloroform was taken as 100%).
Site-directed mutagenesis. Desired mutations were introduced
through the QuikChange site-directed mutagenesis protocol (Agilent
Technologies, USA) with the oligonucleotide primers (and their reverse
complements) listed in Table 2. After PCR for site-directed mutagenesis,
the methylated template strands were digested by 1 l (10 U) of DpnI
restriction enzyme per reaction (at 37°C for 2 h) and purified by Thermo
Scientific GeneJET PCR purification kit, as described by the manufacturer
(Thermo Scientific, Lithuania). Subsequently, 4 l of the purified DNA
was used to transform 40 l of E. coli TOP10 high-competency cells by
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TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristicsa Source or reference
Lactococcus lactis subsp. lactis
BGMN1-596 Plasmid-free derivative of L. lactis subsp. lactis BGMN1-5 18
BGMN1-596R2/23 Mutant of BGMN1-596 semiresistant to LsbB up to 625 g/ml 16
BGMN1-596T BGMN1-596 transformed with pMN5 plasmid 18
Lactococcus lactis subsp. cremoris
MG7284 MG1363, Prt Lac Bacr Fusr Spcr 41
MG7284/pAZIL-lsbB MG7284 transformed with pAZIL-lsbB 16
Enterococcus faecalis
BGZLS10-27 Natural isolate, Agg 42
BGZLS10-27/pAZIL BGZLS10-27 transformed with pAZIL This study
BGZLS10-27/pAZIL-YvjBMN BGZLS10-27 transformed with pAZIL-YvjBMN This study
BGZLS10-27/pAZIL-YvjBMG BGZLS10-27 transformed with pAZIL-YvjBMG This study
Escherichia coli
DH5 supE44 lacU169 (	80lacZM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 43
EC101 JM101 containing repA gene of pWV01 in chromosome 44
TOP10 F mcrA (mrr-hsdRMS-mcrBC) 	80lacZM15 lacX74 recA1 ara139 (ara-leu)7697
galU galK rpsL (Strr) andA1 nupG
Invitrogen
M15(pREP4) Nals Strs Rifs Thi Lac Ara
 Gal




BL21(DE3) B F dcm ampT hsdS (rB
 mB
) gal (DE3) Agilent Technologies
BL21/p-GEX-6P-3/LsbB p-GEX-6P-3/LsbB transformant of BL21 This study
BL21/p-GEX-6P-3 p-GEX-6P-3 transformant of BL21 This study
Plasmids
pMN5 Natural plasmid carrying lsbB operon 18; accession no.
NC_004922.1
pAZIL 7,109 bp, Emr, shuttle cloning vector 45; accession no.
LMBP9596b
pAZIL-lsbB pAZIL carrying lsbB gene 16
pAZIL-lsbB-W25F pAZIL carrying lsbB gene with amino acid change Trp25Phe This study
pAZIL-lsbB-A30-STOP pAZIL carrying lsbB gene with deleted Ala30 amino acid This study




A31 pAZIL carrying lsbB gene with addition of Ala31 amino acid This study
pAZIL-lsbB-A30V pAZIL carrying lsbB gene with amino acid change Ala30Val This study
pAZIL-lsbB-A30G pAZIL carrying lsbB gene with amino acid change Ala30Gly This study
pAZIL-lsbB-A30S pAZIL carrying lsbB gene with amino acid change Ala30Ser This study
pAZIL-lsbB-A30P pAZIL carrying lsbB gene with amino acid change Ala30Pro This study
pAZIL-lsbB-K2N-T3S pAZIL carrying lsbB gene with amino acid changes Lys2Asn and Thr3Ser This study
pAZIL-lsbB-K17A-K19A pAZIL carrying lsbB gene with amino acid changes Lys17Ala and Lys19Ala This study
pAZIL-YvjBMN pAZIL carrying yvjB gene from BGMN1-596 This study
pAZIL-YvjBMG pAZIL carrying yvjB gene from MG7284 This study




pAZIL-YvjBMNB pAZIL carrying yvjB gene from BGMN1-596 with insertion of BamHI restriction
site
This study
pAZIL-YvjB1/2MN-1/2MG pAZIL carrying first half of yvjB gene from BGMN1-596 and second half of yvjB
gene from MG7284 (YvjBMN1-259-YvjBMG260-428 aa)
This study
pAZIL-YvjB1/2MG-1/2MN pAZIL carrying first half of yvjB gene from MG7284 and second half of yvjB gene
from BGMN1-596 (YvjBMG1-256-YvjBMN257-428 aa)
This study
pAZIL-YvjBMGE pAZIL carrying yvjB gene from MG7284 with insertion of EagI restriction site at
position of aa 327 without amino acid changes
This study
pAZIL-YvjBMNE pAZIL carrying yvjB gene from BGMN1-596 with insertion of EagI restriction site
at position of aa 327 without amino acid changes
This study
pAZIL-YvjB3/4MG-1/4MN pAZIL carrying first 3/4 of yvjB gene from MG7284 and 1/4 of yvjB gene from
BGMN1-596 (YvjBMG1-327-YvjBMN328-428 aa)
This study
pAZIL-YvjB1/2MG-1/4MN-1/4MG pAZIL carrying first half of yvjB gene from MG7284, 1/4 of yvjB gene from
BGMN1-596, and last and 1/4 of yvjB gene from MG7284 (YvjBMG1-256-
YvjBMN257-327-YvjBMG328-428 aa)
This study
(Continued on following page)
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heat shock treatment. The Thermo Scientific GeneJET plasmid miniprep
kit was used, according to the manufacturer’s recommendations (Thermo
Scientific), to obtain and purify the plasmids from the selected colonies,
after which sequencing (Macrogen Europe, The Netherlands) was done to
confirm the introduction of the desired mutations.
Preparation of bacterial cell membrane. The method for extracting
cell membrane enzymes from selected lactococcal strains was applied ac-
cording to Attri et al. (30), with modifications.
Cells from the bacterial log cultures (MG7284, BGMN1-596, and
BGMN1-596/23) were harvested by centrifugation at 3,600  g for 10 min
and the cell pellets washed in TEN buffer (50 mM Tris, 10 mM EDTA, 50
mM NaCl [pH 8.0]). Cell pellets (5 g) were suspended in 2 to 3 ml of PP
buffer (see above) with addition of lysozyme (5 mg/ml) and stirred for 1 h
at 37°C. Lysozyme-treated cells were harvested by centrifugation at
1,000  g at 4°C for 5 min, and pellets were resuspended in A buffer (50
mM sodium phosphate, 100 mM NaCl, 0.5% Triton X-100 supplemented
with the protease inhibitor cocktail at a 1:200 [vol/vol] ratio [pH 8.0]).
The cells were subjected to sonication for 1 min at a frequency of 8 kHz
while being kept in an ice bath. The homogenate was centrifuged at 16,000
 g for 30 min to obtain the supernatant. In the next step, the supernatant
was centrifuged at 100,000  g for 18 h at 4°C to pellet the cell membranes.
Pellets containing cellular membranes were resuspended in B buffer (20
mM Tris, 5 mM MgCl2, 0.01 mM Zn
2
 supplemented with the protease
inhibitor cocktail at a 1:200 [vol/vol] ratio [pH 6.8]).
In order to obtain more pure membrane fractions, homogenates were
centrifuged at 45,000  g for 5 h at 4°C. Supernatants representing cell
cytoplasm and pellets representing the membrane fraction were stored in
an ice bath (up to 7 days).
Production of polyclonal antibody. Synthetic LsbB (ChinaPeptides
Co., Ltd., Shanghai, China) was used for production of anti-LsbB poly-
clonal antibody.
Two regions of YvjB protein (YvjBex1 from 80th to 185th amino acids
and YvjBex2 from 225th to 300th amino acids) that do not contain inter-
membrane domains were expressed using the pQE30 6His tag (Qiagen)
expression system for the production of anti-YvjB polyclonal antibody.
First, using total DNA BGMN1-596 and designed primers ex1 SacI/
HindIII for YvjBex1, and ex2 BamHI/HindIII for YvjBex2, corresponding
fragments were amplified by PCR. The PCR products were purified and
cloned first to pGEM-T-Easy vector, confirmed by sequencing, and re-
cloned as SacI/HindIII or BamHI/HindIII in frame with 6His tag to
pQE30 expression vector. Fusion His-tagged proteins were expressed in E.
coli M15 cells.
His tag affinity purification of YvjBex1 and YvjBex2 proteins was con-
ducted under denaturing conditions. The refolding method using urea to
TABLE 1 (Continued)
Strain or plasmid Relevant characteristicsa Source or reference
pAZIL-YvjBMG-L351F pAZIL carrying yvjB gene from MG7284 with amino acid change Leu
351Phe This study
pAZIL-YvjBMG-T353A pAZIL carrying yvjB gene from MG7284 with amino acid change Thr
353Ala This study
pAZIL-YvjBMG-Q356Y pAZIL carrying yvjB gene from MG7284 with amino acid change Gln
356Tyr This study
pAZIL-YvjBMG-P396Q pAZIL carrying yvjB gene from MG7284 with amino acid change Pro
396Gln This study
























pAZIL-YvjBMG-L351F-T353A-Q356Y-P396Q pAZIL carrying yvjB gene from MG7284 with amino acid changes Leu
351Phe,
Thr353Ala, Gln356Tyr, and Pro396Gln
This study
pAZIL-YvjBMG-L351F-T353A-Q356Y-T314A pAZIL carrying yvjB gene from MG7284 with amino acid changes Leu
351Phe,
Thr353Ala, Gln356Tyr, and Thr314Ala
This study
pBluescript 2,958 bp, Ampr, cloning vector Stratagene
pGEM-T-Easy 3,015 bp, Ampr, PCR cloning vector Promega
pGEM-T-YvjBex1 PCR-amplified fragment carrying region of YvjB protein between first and second
transmembrane domains cloned into pGEM-T-Easy
This study
pGEM-T-YvjBex2 PCR-amplified fragment carrying region of YvjB protein between second and
third transmembrane domains cloned into pGEM-T-Easy
This study
pGEX-6P-3 4,900 bp, Ampr, GST expression vector GE Healthcare Life
Sciences
pGEX-6P-3/GST-LsbB Cloned lsbB gene into pGEX-6P-3 vector, GST-LsbB fusion protein This study
pQE30 Amp
r, ColE1 replicon, 6His expression vector Qiagen
pQE30-YvjBex1 PCR-amplified fragment carrying region of YvjB protein between first and second
transmembrane domains cloned as SacI/HindIII into pQE30
This study
pQE30-YvjBex2 PCR-amplified fragment carrying region of YvjB protein between second and
third transmembrane domains cloned as BamHI/HindIII into pQE30
This study
pNZ8150lacZ1PlcnB PlcnB promoter cloned into pNZ8150lacZ1 vector 28
a Agg, aggregative protein negative; Prt, proteinase negative; Lac, lactose utilization negative; Bacr, bacteriocin resistant; Fusr, fusaric acid resistant; Spcr, spectinomycin
resistant; Strr, streptomycin resistant; Nals, nalidixic acid susceptible; Strs, streptomycin susceptible; Rifs, rifampin susceptible; Emr, erythromycin resistant; Ampr, ampicillin
resistant; aa, amino acid.
b LMBP9596, BCCM plasmid collection accession number.
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disrupt noncovalent bonds and increase protein solubility was used to
solubilize and make the His-tagged YvjBex1 and YvjBex2 more accessible
to the nickel-nitrilotriacetic acid (Ni-NTA) resin. The recombinant pro-
teins were purified according to the protocol recommended by The QIA-
expressionist (Qiagen). The eluted proteins were dialyzed by ultrafiltra-
tion (centrifugal filter units; Amicon Ultra-15 centrifugal filter devices,
3K; Millipore). Polyclonal antibodies were produced by immunization of
mice with the synthetic or purified fusion proteins in the animal house of
the International Centre for Genetic Engineering and Biotechnology
(ICGEB), Trieste, Italy.
Construction of GST-LsbB-tag protein and GST pulldown assay.
Specific sets of primers [LsbB-tag(GST)-F and LsbX-Sal-R; Table 2] were
designed for amplification of selected a part of the lsbB gene from pMN5
plasmid DNA. The PCR product was purified and cloned to pGEM-T-
Easy vector and confirmed by sequencing. The lsbB gene was transferred
from pGEM-T-Easy as a BamHI/SalI fragment into the expression vector
pGEX-6P-3 to obtain glutathione S-transferase (GST)-LsbB fusion pro-
tein. After transforming the expression vector into competent E. coli BL21
cells, BL21/p-GEX-6P-3/LsbB and BL21/p-GEX-6P-3 (control strain with
empty vector) were grown in 50 ml of LB broth (containing 100 g/ml
TABLE 2 Primers used in this study















LsbB-tag (GST)-F GGATCCATGAAAACAATCCTACG pMN5
LsbX-SalI-R GTTGTCGACTAATCAATATGTTCC pMN5
ORFF GGCGTAAAAGATTCAGG Total DNA BGMN1-596 or MG7284
ORFR GAAGGGTTGGTATAAGC Total DNA BGMN1-596 or MG7284
MGBH257G-F GAAATTTCAGGATCCAATGGAAAAG pAZIL-YvjBMN pAZIL-YvjBMG
MGBH257G-R CCATTGGATCCTGAAATTTCTGTGACC pAZIL-YvjBMN pAZIL-YvjBMG
MGBH257G-259K-F GAAATTTCAGGATCCAAAGGAAAAG pAZIL-YvjBMN pAZIL-YvjBMG
MGBH257G-259K-R CCTTTGGATCCTGAAATTTCTGTGACC pAZIL-YvjBMN pAZIL-YvjBMG
Eag-F GATTGCACGGCCGAGTCTTG pAZIL-YvjBMN pAZIL-YvjBMG





























a Restriction sites are underlined; changed amino acid codons are indicated by bold type.
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ampicillin) to an OD600 (A600) of 0.6, with vigorous agitation at 37°C.
Before the next step, 1 ml of the cultures was collected (noninduced sam-
ples). Fusion protein expression was induced by 0.1 mM isopropyl--D-
thiogalactoside (IPTG) (Sigma-Aldrich) by incubating the cultures for an
additional for 2 h at 28°C. One milliliter of the cultures was collected
(induced samples) and analyzed. Noninduced and induced samples for
both strain BL21/p-GEX-6P-3/LsbB and BL21/p-GEX-6P-3 were boiled
for 2 min and checked by protein gel electrophoresis (12.5% gel) prior to
Coomassie blue staining. The rest of the BL21/p-GEX-6P-3/LsbB and
BL21/p-GEX-6P-3 (control strain) bacterial cultures were harvested by
centrifugation at 4,500  g for 10 min, and the cell pellets were suspended
in 3 ml of lysis buffer containing 0.5% Triton X-100, 0.2% SDS, 0.5%
NP-40, and 0.1% Tween 20. The cells were lysed in the ice for 30 min with
gentle agitation. The lysates were subjected to sonication for 1 min (6
times 10 s) at a frequency of 10 kHz while being kept in an ice bath. The
homogenate was centrifuged at 10,000  g for 30 min at 4°C to obtain the
supernatant.
In order to bind the engineered tagged protein to the matrix, super-
natants of BL21/p-GEX-6P-3/LsbB and BL21/p-GEX-6P-3 were incu-
bated with glutathione Sepharose 4 Fast Flow (GE Healthcare, Germany)
for 2 h at 4°C with continuous mixing.
Beads of glutathione Sepharose (200 l) with bound proteins were
centrifuged briefly and washed with the same lysis buffer at 4°C. The
quantity of GST-LsbB fusion protein and GST protein (20 l per each)
was tested by SDS-PAGE and Western blot analysis using anti-LsbB anti-
body. Equal amounts of beads with bound GST-LsbB and GST (50 l
each) proteins were homogeneously mixed with the membrane fractions
of strains MG7284, BGMN1-596, and BGMN1-596R2/23 (50 l each)
and made up to a volume of 600 l with supplement buffer (50 mM Tris,
120 mM NaCl [pH 6.8]). The mixture was incubated overnight at 4°C
with gentle agitation, washed five times for 30 min each in phosphate-
buffered saline (PBS) buffer (10 mM Na2HPO4, 1 mM KH2PO4, 140 mM
NaCl, 3 mM KCl [pH 7.1]), and protein complexes were pulled down.
Western blotting. Protein(s) associated with the GST-LsbB fusion
protein and GST protein was analyzed by SDS-PAGE and Western blot
assays using anti-YvjB and anti-LsbB antibodies (independently). Sam-
ples were loaded into a 12.5% polyacrylamide gel, subjected to electro-
phoresis, and transferred to a polyvinylidene difluoride (PVDF) mem-
brane (Merck Millipore, Darmstadt, Germany) for 1 h at appropriate
voltage (constant voltage). Membranes were incubated with 10% skim
milk in Tris-buffered saline containing 0.1% Tween 20 (TBST) overnight
at 4°C in order to block nonspecific binding. Following blocking, the
membranes were incubated for 1 h at RT with gentle agitation in appro-
priate dilutions of primary antibodies, as follows: mouse polyclonal anti-
body anti-YvjB, 1:3,000 dilution, and mouse polyclonal antibody anti-
LsbB, 1:5,000 dilution (independently). Primary antibodies were diluted
in 5% skim milk in TBST. After washing three times in TBST for 15 min,
membranes were incubated for 1 h with horseradish peroxidase-labeled
anti-mouse IgG (A9044 anti-mouse; Sigma) at a 1:10,000 dilution in 5%
skim milk in TBST. The blots were washed three times in TBST for 15 min.
Bands of target proteins were detected using the CN/DAB substrate kit
(Thermo Scientific), according to the manufacturer’s instructions.
Immunocytochemistry. After plating on coverslips, bacterial cells
were fixed in 4% paraformaldehyde (PFA) for 20 min at RT. Cells were
blocked in 5% bovine serum albumin (BSA) in PBS for 1 h at RT. Primary
antibodies were diluted in PBS containing 1% BSA and incubated over-
night at 4°C with mouse polyclonal anti-LsbB (this study, diluted 1:50).
Coverslips were washed three times for 10 min in PBS and incubated with
biotinylated goat anti-mouse IgG (Vector, Burlingame, CA, USA) for 1 h
at RT in 1% BSA, followed by Cy3-streptavidin (diluted 1:5,000; Jackson
ImmunoResearch, West Grove, PA, USA) diluted in PBS for 1 h at RT.
Bacterial DNA was stained with 0.1 mg/ml 4=,6-diamino-2-phenylindole
(DAPI; Sigma-Aldrich). Samples were visualized under an Olympus BX51
fluorescence microscope with appropriate filters and analyzed using the
CytoVision 3.1 software (Applied Imaging Corporation, USA).
RESULTS
LsbB causes membrane damage of sensitive cells. To determine
whether LsbB causes membrane damage, different lactococcal
strains with different levels of sensitivity to LsbB were exposed to
synthetic LsbB. These were the resistant strain MG7284, the sen-
sitive strain BGMN1-596, and the semisensitive mutant BGMN1-
596R2/23 (see Table 1). The strains were transformed with
pNZ8150lacZ1PlcnB encoding -galactosidase, which was used as
a reporter system for the detection of membrane damage. The
results showed that the level of -galactosidase activity (and thus
membrane damage) is directly correlated with the level of sensi-
tivity to LsbB (see Fig. S1 in the supplemental material), i.e., more
-galactosidase activity was found in sensitive cells than in less-
sensitive cells. The results provide evidence that LsbB kills target
cells by membrane damage.
Identification of essential amino acid residues in LsbB bacte-
riocin involved in antimicrobial activity. We have previously
demonstrated that the last C-terminal 8 amino acids of the LsbB
bacteriocin are involved in the interaction with the receptor pro-
tein YvjB (23). The residue Trp25 plays a particularly important
role, as the substitution Trp25 to Ala caused a total loss of antimi-
crobial activity. To further study the importance of Trp25 and
other amino acids in receptor binding, additional amino acid sub-
stitutions were made in LsbB (Fig. 1). It was found that the sub-
stitution of Trp25 with Phe, an amino acid belonging to the same
aromatic group, caused a small reduction in bacteriocin activity,
indicating the involvement of specific groups on amino acid 25 in
specific interactions with YvjB (Fig. 1B). Previous work indicates
that the last residue, Ala30, is important for bacteriocin activity. As
expected, the deletion of the terminal Ala30, the addition of an-
other alanine at the end (Ala31), or the substitution of Ala30 with
Pro caused a total loss of antimicrobial activity of LsbB, whereas
substitutions of Ala30 with other residues, such as Gly and Val, had
no apparent impact on the bacteriocin activity, while substitution
with Ser enhanced bacteriocin activity (Fig. 1A). In our previous
FIG 1 Antimicrobial activity of LsbB-derived mutants. (A) Modifications at
or near residue Ala30. 1, Ala30; 2, Ala30 plus Ala31; 3, Ala30Val; 4, Ala30Gly; 5,
Ala30Ser; 6, Ala30Pro; 7, BGMN1-596T; 8, MG7284/pAZIL-lsbB (a and b are
two colonies from the same transformation). (B) Trp25Phe substitution. (C)
Lys17Ala plus Lys19Ala substitution. (D) Lys2Asn plus Thr3Ser substitutions.
(E) Lys29Ala plus Ala30 substitutions. (B to E) 1, mutated LsbB; 2, MG7284/
pAZIL-lsbB; 3, BGMN1-596T; 4, BGMN1-596; 5, mutated LsbB with one
Lys29Ala substitution. Cultures of transformants were introduced into wells
made in soft agar inoculated with indicator strain L. lactis BGMN1-596. The
size of the zone is referred to the clone containing the wild-type lsbB gene
(MG7284/pAZIL-lsbB). Inhibition is seen as clear zones around the wells.
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work (23), we demonstrated that the Lys29Ala mutation increased
bacteriocin activity. To assess whether this substitution (Lys29Ala)
can replace the importance of the terminal alanine Ala30, we cre-
ated a double mutant with Lys29Ala and Ala30; thus, the resulting
peptide was only 29 residues, with alanine as the last residue. As
shown in Fig. 1E, this double mutant did not exert any antimicro-
bial activity at all. These results confirmed that the residues Trp25
and Ala30 are both important for LsbB’s antimicrobial activity,
although Ala30 appeared to tolerate to some extent a substitution
with another aliphatic amino acid or serine. The results might also
indicate that the distance between Trp25 and the last alanine is
crucial, as shortening (termination with Ala29 instead of Ala30) or
elongation (addition of Ala31) of this distance seriously affected
the antimicrobial activity.
To assess the importance of the N-terminal half, we created a
double mutant; Lys2 and Thr3 were changed to Asn2 and Ser3,
respectively. The activity of the modified peptide did not change
drastically (Fig. 1D), indicating that the N-terminal part of LsbB
seems to be less sensitive to changes/modifications.
One of the peptides (LcnG-) of the two-peptide bacteriocin
lactococcin G (like LsbB) contains a series of cationic residues
(Arg35Lys36Lys37Lys38His39) at the C-terminal part, and it has
been proposed that this feature functions as a means to force the
peptide to the target cell membrane by electrostatic interaction
(31). LsbB contains a similar string of basic residues in its C-ter-
minal half (His16Lys17Lys18Lys19Thr20). To examine whether this
feature has a similar function, the number of cationic residues in
this feature was reduced by changing His16Lys17Lys18Lys19Thr20 to
His16Ala17Lys18Ala19Thr20, thus reducing the pI from 10.99 to
10.50. The resulting mutant peptide did not have any apparent
adverse effect on bacteriocin activity; in fact, it even slightly en-
hanced the activity (Fig. 1C).
Based on all these amino acid substitutions, deletions, and ad-
ditions, it is possible to conclude that the C-terminal part of the
LsbB bacteriocin is most important for bacteriocin activity, likely
through interaction with the receptor protein YvjB.
Mapping of the region on YvjB involved in LsbB interaction.
It has previously been established that among lactococci, there
exist both sensitive and resistant strains to LsbB, such as the resis-
tant strain MG7284 and the sensitive strain BGMN1-596, both of
lactococcal genotype. The LsbB-resistant strain MG7284 pos-
sesses a homolog of YvjB (YvjBMG) that differs in 31 residues from
the YvjB of the sensitive strain BGMN1-596 (YvjBMN). These dif-
ferences appear to be randomly distributed over the entire protein
length (Fig. 2). To search for the regions in YvjBMN and YvjBMG
that cause their different sensitivity to LsbB, hybrid proteins con-
taining portions of both proteins were constructed (see Fig. S2 in
the supplemental material). A hybrid protein containing the C-
terminal half of YvjBMN and the N-terminal half of YvjBMG
(YvjB1/2MG-1/2MN) was able to confer sensitivity to LsbB when ex-
pressed in strain MG7284 (naturally resistant to LsbB), indicating
that the C-terminal half of YvjBMN is involved in target specificity.
Further, a hybrid protein (YvjB3/4MG-1/4MN) with an even smaller
part of YvjBMN at the C terminus was still capable of conferring
sensitivity to LsbB. Different hybrid combinations, as depicted in
Fig. S2, further confirmed that the last section of the C terminus of
YvjB is most likely involved in direct interaction with LsbB and
consequently in sensitivity to the bacteriocin.
Given that the potential LsbB-binding domain is located at the
C-terminal end of YvjB, we are interested in finding the mem-
FIG 2 Comparison of the amino acid sequences of YvjBMN and YvjBMG using Strider software. All amino acid differences are indicated by red stars for ones
belonging to the same physicochemical group and by black stars for ones belonging to different physicochemical groups. Underlined amino acids represent
transmembrane domains.
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brane topology of this part. Using Phobius (http://phobius.binf
.ku.dk/index.html) or TMHMM server version 2.0 for prediction
of transmembrane (TM) helices in proteins (http://www.cbs.dtu
.dk/services/TMHMM/), YvjB was predicted to possess four
transmembrane (TM) domains: TMI from amino acids (aa) 5 to
27, TMII from aa 188 to 210, TMIII from aa 354 to 376, and TMIV
from aa 401 to 423 (Fig. 2; see also Fig. S3 in the supplemental
material). Based on this prediction, the LsbB-binding domain is
likely located within the region containing two transmembrane
helices connected by a noncytoplasmic hinge.
Further defining the amino acids involved in receptor func-
tion by site-directed mutagenesis. The hybrid molecule
YvjB3/4MG-1/4MN contains the last part of the YvjBMN protein,
which differs from YvjBMG in six positions (amino acids Phe
351,
Ala353, Val354, Tyr356, Gln396, and Met404 in YvjBMN are different
in comparison to those present at the same positions Leu351,
Thr353, Ile354, Gln356, Pro396, and Leu404 in YvjBMG) (Fig. 2). Some
of these differences are likely responsible for the observed differ-
ence between YvjBMG and YvjBMN in terms of sensitivity to LsbB.
Four of YvjBMG’s six amino acids belong to different physico-
chemical groups from the ones in YvjBMN. These were therefore
mutated separately and in combination, in both the YvjBMG and
YvjB3/4MN-1/4MG proteins (in constructs pAZILyvjBMG and
pAZILyvjB3/4MN-1/4MG, respectively), into the residues present in
YvjBMN in order to determine which amino acid(s) is directly
responsible for the sensitivity to LsbB. In the first round of mu-
tagenesis (single amino acid changes), it is worth noting that
Tyr356 was able to transform carrier cells from a resistant to a
sensitive phenotype (Fig. 3). This sensitivity occurred, in fact, in
both tested YvjB proteins (MG7284/YvjBMG and MG7284/
YvjB3/4MN-1/4MG), although the zone of inhibition by BGMN1-
596T as an LsbB producer was smaller than for YvjBMN. This
smaller zone of inhibition indicated a possible additional effect of
other amino acids in the interaction with LsbB. In the second
round of site-directed mutagenesis (when different combinations
of two, three, or four amino acids were changed), some interesting
results were obtained, as depicted in Fig. 3. First, only the changes
in combination with Gln356Tyr could cause sensitivity of the car-
riers. However, the zones of inhibition of these mutants were dif-
ferent in size and transparency; for example, adding the change
Leu351Phe to Gln356Tyr slightly increased the clear inhibition zone
(Fig. 3). Additionally, the change Gln356Tyr plus Thr353Ala dras-
tically increased the zone of inhibition, which was even larger than
with YvjBMN: however, it contained a high number of revertant-
like resistant colonies (Fig. 3; see also Fig. S4 in the supplemental
material). Triple and quadruple amino acid changes to YvjBMG
and YvjB3/4MN-1/4MG showed that additional changes reduced the
number of revertant-like resistant bacteria in the inhibition zone
and restored the size of the zone to the size obtained with YvjBMN.
In summary, it was concluded that the amino acid in the YvjB
receptor most responsible for the interaction with LsbB and the
sensitivity of cells to LsbB is Tyr356, whereas the other amino acids
are also important but to a lesser extent than Tyr356.
It is worth noting that the residue Tyr356 is located at the be-
ginning of the predicted third transmembrane helix (from residue
355 to residue 376), with the C-terminal end pointing toward the
cytoplasm. More important, Tyr356 is closely flanked by three res-
idues that differentiate YvjBMG from YvjBMN in this region, sug-
gesting that these residues together probably form a site to which
LsbB binds to kill target cells.
LsbB interacts directly with YvjB. It was of interest to deter-
mine if the LsbB bacteriocin interacts directly with the YvjB
receptor.
In a GST pulldown assay, LsbB coupled to GST (it was decided
to fuse the GST tag at the N terminus of LsbB, as our previous
studies determined that the C terminus was important for the
interaction with the target receptor [23]) was able to bind YvjBMN
protein from membrane fractions and to retain it during stringent
washing (Fig. 4). Similar experiments determined that YvjBMG
and YvjBMNR2/23 proteins were able to bind LsbB but much less
efficiently than YvjBMN (Fig. 4B, lanes 2, 9, and 5, respectively). In
the control reaction with GST alone, no unspecific binding was
detected (Fig. 4B, lanes 3, 6, and 8, respectively).
The GST pulldown assay is an in vitro assay. Thus, to determine
the interaction in vivo, an analysis with fluorescent antibodies
against YvjB and LsbB proteins was performed in live cells. The
immunocytochemistry assay was performed with transformants
of E. faecalis BGZLS10-27 harboring the pAZIL vector carrying
different yvjB genes (yvjBMN and yvjBMG). We used the enterococ-
cal strain as a host, because there was no lactococcal strain without
endogenous YvjB protein to serve as a negative control (the neg-
FIG 3 Antimicrobial activity of LsbB on different mutants obtained by site-
directed mutagenesis of YvjBMG protein. Cultures of MG7284 transformants
carrying different amino acid substitutions of YvjB protein were inoculated as
indicator strains into soft agar in which wells were loaded with L. lactis
BGMN1-596T. The size of the zone is referred to the clone containing the
wild-type yvjB gene (L. lactis BGMN1-596). Inhibition is seen as clear zones
around the wells. , no inhibition; 




inhibition zone 5 mm; aa, amino acid.
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ative control was strain BGZLS10-27 transformed with empty
pAZIL vector). In addition, this particular enterococcal strain was
used because it was resistant to LsbB and nonreactive with the
antibodies used (data not shown). Before beginning this assay, the
sensitivity of BGZLS10-27 transformants carrying different con-
structs was confirmed by an antimicrobial assay (see Fig. S5 in the
supplemental material). The in vivo immunocytochemistry assay
showed that LsbB interacts specifically with the cells expressing
YvjBMN (Fig. 5). Full matching of the color that locates the pres-
ence of transformed cells (DAPI) and fluorescent antibody that
locates LsbB bacteriocin (LsbB) is obtained only when transfor-
mants BGZLS10-27/pAZIL-YvjBMN (merge) were used. In exper-
iments that used the transformants carrying empty plasmid
BGZLS10-27/pAZIL (control) or cloned YvjB gene from the strain
MG7284 (BGZLS10-27/pAZIL-YvjBMG), colocalization of these
two signals was not obtained.
DISCUSSION
In recent years, two important needs have emerged: the increasing
consumer demand for natural food preservatives, such as bacte-
riocins produced by lactic acid bacteria, and the demand for new
antimicrobial compounds in response to the continuing emer-
gence of antibiotic-resistant bacteria, in the face of declining num-
bers of new antibiotics (32–34). Consequently, the research and
application of bacteriocins are ever-more-attractive propositions.
Until now, it has been shown that the antimicrobial activity of
bacteriocins is directly related to the presence of specific receptor
proteins in the membranes of target bacteria. Thus, information
on the receptors to which bacteriocins bind is potentially of great
importance (4).
In our previous studies, we identified the Zn-dependent met-
allopeptidase YvjB as the receptor for the bacteriocin LsbB (16)
and further established that the C-terminal part of LsbB is in-
volved in the interaction with the receptor protein YvjB (23). In
this work, we combined site-directed mutagenesis with the con-
struction of hybrid protein molecules to define the residues of
LsbB and YvjB involved in the interactions that eventually lead to
the killing of target cells. We demonstrated that the essential
amino acids are Trp25 and Ala30 in the LsbB C terminus and Tyr356
and Ala353 in the penultimate transmembrane domain of YvjB
receptor.
FIG 4 GST pulldown assay with purified cell membranes. (A) Western blot with anti-LsbB antibody. (B) Western blot with anti-YvjB antibody. Lane 1, total cell
membrane fraction of MG7284; lane 2, proteins that interacted with GST-LsbB from the cell membrane fraction of MG7284; lane 3, proteins that interacted with
GST from the cell membrane fraction of MG7284; lane 4, total cell membrane fraction of BGMN1-596; lane 5, proteins that interacted with GST-LsbB from the
cell membrane fraction of BGMN1-596; lane 6, proteins that interacted with GST from the cell membrane fraction of BGMN1-596; lane 7, total cell membrane
fraction of BGMN1-596R2/23; lane 8, proteins that interacted with GST from the cell membrane fraction of BGMN1-596R2/23; lane 9, proteins that interacted
with GST-LsbB from the cell membrane fraction of BGMN1-596R2/23; lane 10, Spectra multicolor broad range protein ladder (Thermo Fisher Scientific). The
quantities of proteins of membrane fractions of MG7284, BGMN1-596, and BGMN1-596R2/23 were normalized to 100 g per reaction. The white arrow
indicates the GST-LsbB fusion protein, while the black arrow indicates YvjBMN protein from the GST pulldown assay.
FIG 5 Immunocytochemistry assay with anti-LsbB antibodies was performed
on transformants of Enterococcus faecalis BGZLS10-27 with pAZIL vector
(control), pAZIL-YvjBMG (YyjBMG), and pAZIL-YvjBMN (YvjBMN). Bacte-
rial DNA was stained with 4=,6-diamino-2-phenylindole (DAPI).
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Such a site-directed mutagenesis approach has been used for
amino acid substitution in different bacteriocins of lactic acid bac-
teria to analyze function or to improve antimicrobial activity (35–
40). The results obtained by site-directed mutagenesis of the LsbB
bacteriocin are consistent with data obtained by other laborato-
ries, where most amino acid substitutions cause a reduction in or
complete loss of activity. It is interesting, however, that some sub-
stitutions, such as alanine to serine (Ala30Ser), enhanced bacteri-
ocin activity, most likely due to better interaction and positioning
in the YvjB receptor. In addition, we suggest that not only residues
Trp25 and Ala30, but also the distance between them, play an es-
sential role in the antimicrobial activity of LsbB.
The construction of hybrid molecules and site-directed mu-
tagenesis with structure-function assays enabled us to define es-
sential domains responsible for the interaction of the target recep-
tor YvjB with LsbB. It is interesting that all key amino acids
involved in the interaction with LsbB are located in the beginning
of the penultimate transmembrane domain of YvjB (Fig. 2; see
also Fig. S3 in the supplemental material). The Gly188Ser mutant
obtained by random mutagenesis (16) also includes changes in the
beginning of the second transmembrane domain and shows a
semiresistant phenotype. From the results presented here, it is
possible to conclude that these regions are most likely accessible
for interaction with LsbB. It is interesting that the beginning of the
third transmembrane domain (amino acids Ala353, Val354, and
Tyr356) seems to be very close to the outside surface of the mem-
brane, possibly making it accessible for LsbB interaction (see Fig.
S3). In contrast, the beginning of the second transmembrane do-
main is located closer to the cytoplasmic side, indicating that both
sides of the membrane are involved in the interaction of YvjB with
LsbB, causing membrane damage of cells. It could be postulated
that the third transmembrane domain is involved in the first in-
teraction with LsbB, but the second transmembrane domain is
also important for complex formation and membrane damage of
sensitive cells. Mutants with an amino acid substitution in the
second transmembrane domain, such as Gly188Ser, are semiresis-
tant, meaning that they can interact with LsbB on the surface but
require higher concentrations of LsbB for complex formation and
membrane damage of the cells. Given that LsbB in vitro was able to
interact with all three YvjB proteins (from resistant strain
MG7284, semiresistant mutant BGMN1-596R2/23, and sensitive
strain BGMN1-596) but not in vivo indicates the involvement of
other factors present in cell wall in the control of the interaction.
Any changes to the essential amino acids in the bacteriocin recep-
tor protein cause partial or complete resistance to certain bacte-
riocins. For this reason, it is important to identify specific recep-
tors for bacteriocins and the domains involved in the interaction.
The identification of new bacteriocin receptors present in poten-
tial target bacteria and understanding of their mechanisms of ac-
tion are of great importance for the design of target-specific engi-
neered antimicrobials.
ACKNOWLEDGMENTS
The Ministry of Education and Science of the Republic of Serbia, Republic
of Serbia (grant 173019), supported this work.
We thank the personnel of the Animal House of ICGEB for excel-
lent technical assistance during the immunization of animals and
blood sampling.
FUNDING INFORMATION
This work, including the efforts of Marija Miljkovic, Gordana Uzelac,
Nemanja Mirkovic, Giulia Devescovi, Dzung B. Diep, Vittorio Venturi,
and Milan Kojic, was funded by Ministarstvo Prosvete, Nauke i
Tehnološkog Razvoja (Ministry of Education, Science and Technological
Development) (173019).
REFERENCES
1. Cotter PD, Hill C, Ross RP. 2005. Bacteriocins: developing innate im-
munity for food. Nat Rev Microbiol 3:777–788. http://dx.doi.org/10.1038
/nrmicro1273.
2. Nes IF, Yoon SS, Diep DB. 2007. Ribosomally synthesized antimicrobial
peptides (bacteriocins) in lactic acid bacteria: a review. Food Sci Biotech-
nol 16:675– 690.
3. Rea MC, Cotter PD, Hill C, Ross RP. 2011. Classification of bacteriocins
from Gram-positive bacteria, p 29 –53. In Drider D, Rebuffat S (ed), Pro-
karyotic antimicrobial peptides–from genes to applications. Springer,
New York, NY.
4. Cotter PD. 2014. An ‘Upp’-turn in bacteriocin receptor identification.
Mol Microbiol 92:1159 –1163. http://dx.doi.org/10.1111/mmi.12645.
5. Perez RH, Zendo T, Sonomoto K. 2014. Novel bacteriocins from lactic
acid bacteria (LAB): various structures and applications. Microb Cell Fact
13(Suppl 1):S3. http://dx.doi.org/10.1186/1475-2859-13-S1-S3.
6. Bastos MDC, Coelho ML, Santos OC. 2015. Resistance to bacteriocins
produced by Gram-positive bacteria. Microbiology 161:683–700. http:
//dx.doi.org/10.1099/mic.0.082289-0.
7. Chen H, Hoover DG. 2003. Bacteriocins and their food applications.
Compr Rev Food Sci Food Saf 2:82–100. http://dx.doi.org/10.1111/j.1541
-4337.2003.tb00016.x.
8. Cavera VL, Arthur TD, Kashtanov D, Chikindas ML. 2015. Bacteriocins
and their position in the next wave of conventional antibiotics. Int J An-
timicrob Agents 46:494 –501. http://dx.doi.org/10.1016/j.ijantimicag
.2015.07.011.
9. Martin NI, Breukink E. 2007. Expanding role of lipid II as a target for
lantibiotics. Future Microbiol 2:513–525. http://dx.doi.org/10.2217
/17460913.2.5.513.
10. Müller A, Ulm H, Reder-Christ K, Sahl HG, Schneider T. 2012. Inter-
action of type A lantibiotics with undecaprenol-bound cell envelope pre-
cursors. Microb Drug Resist 18:261–270. http://dx.doi.org/10.1089/mdr
.2011.0242.
11. Münch D, Muller A, Schneider T, Kohl B, Wenzel M, Bandow JE,
Maffioli S, Sosio M, Donadio S, Wimmer R, Sahl HG. 2014. The
lantibiotic NAI-107 binds to bactoprenol bound cell wall precursors and
impairs membrane functions. J Biol Chem 289:12063–12076. http://dx
.doi.org/10.1074/jbc.M113.537449.
12. Martínez B, Bottiger T, Schneider T, Rodriguez A, Sahl HG, Wiede-
mann I. 2008. Specific interaction of the unmodified bacteriocin lacto-
coccin 972 with the cell wall precursor lipid II. Appl Environ Microbiol
74:4666 – 4670. http://dx.doi.org/10.1128/AEM.00092-08.
13. Diep DB, Skaugen M, Salehian Z, Holo H, Nes IF. 2007. Common
mechanisms of target cell recognition and immunity for class II bacterio-
cins. Proc Natl Acad Sci U S A 104:2384 –2389. http://dx.doi.org/10.1073
/pnas.0608775104.
14. Kjos M, Salehian Z, Nes IF, Diep DB. 2010. An extracellular loop of the
mannose phosphotransferase system component IIC is responsible for
specific targeting by class IIa bacteriocins. J Bacteriol 192:5906 –5913. http:
//dx.doi.org/10.1128/JB.00777-10.
15. Gabrielsen C, Brede DA, Hernández PE, Nes IF, Diep DB. 2012. The
maltose ABC transporter in Lactococcus lactis facilitates high-level sensi-
tivity to the circular bacteriocin garvicin ML. Antimicrob Agents Che-
mother 56:2908 –2915. http://dx.doi.org/10.1128/AAC.00314-12.
16. Uzelac G, Kojic M, Lozo J, Aleksandrzak-Piekarczyk T, Gabrielsen C,
Kristensen T, Nes IF, Diep DB, Topisirovic L. 2013. A Zn-dependent
metallopeptidase is responsible for sensitivity to LsbB, a class II leaderless
bacteriocin of Lactococcus lactis subsp. lactis BGMN1-5. J Bacteriol 195:
5614 –5621. http://dx.doi.org/10.1128/JB.00859-13.
17. Kjos M, Oppegård C, Diep DB, Nes IF, Veening JW, Nissen-Meyer J,
Kristensen T. 2014. Sensitivity to the two-peptide bacteriocin lactococcin
G is dependent on UppP, an enzyme involved in cell-wall synthesis. Mol
Microbiol 92:1177–1187. http://dx.doi.org/10.1111/mmi.12632.
18. Kojic M, Strahinic I, Fira D, Jovcic B, Topisirovic L. 2006. Plasmid
content and bacteriocin production by five strains of Lactococcus lactis
LsbB and Its Receptor YvjB Directly Interact
September 2016 Volume 82 Number 17 aem.asm.org 5373Applied and Environmental Microbiology
 on D
ecem








isolated from semi-hard homemade cheese. Can J Microbiol 52:1110 –
1120. http://dx.doi.org/10.1139/w06-072.
19. Kroos L, Akiyama Y. 2013. Biochemical and structural insights into
intramembrane metalloprotease mechanisms. Biochim Biophys Acta
1828:2873–2885. http://dx.doi.org/10.1016/j.bbamem.2013.03.032.
20. Akiyama K, Mizuno S, Hizukuri Y, Mori H, Nogi T, Akiyama Y. 2015.
Roles of the membrane-reentrant -hairpin-like loop of RseP protease in
selective substrate cleavage. eLife 4:e08928. http://dx.doi.org/10.7554/eLife
.08928.
21. Hizukuri Y, Oda T, Tabata S, Tamura-Kawakami K, Oi R, Sato M,
Takagi J, Akiyama Y, Nogi T. 2014. A structure-based model of substrate
discrimination by a noncanonical PDZ tandem in the intramembrane-
cleaving protease RseP. Structure 22:326 –336. http://dx.doi.org/10.1016
/j.str.2013.12.003.
22. Varahan S, Iyer VS, Moore WT, Hancock LE. 2013. Eep confers ly-
sozyme resistance to Enterococcus faecalis via the activation of the extracy-
toplasmic function sigma factor SigV. J Bacteriol 195:3125–3134. http:
//dx.doi.org/10.1128/JB.00291-13.
23. Ovchinnikov K, Kristiansen PE, Uzelac G, Topisirovic L, Kojic M,
Nissen-Meyer J, Nes IF, Diep DB. 2014. Defining the structure and
receptor binding domain of the leaderless bacteriocin LsbB. J Biol Chem
289:23838 –23845. http://dx.doi.org/10.1074/jbc.M114.579698.
24. Kojic M, Svircevic J, Banina A, Topisirovic L. 1991. Bacteriocin-
producing strain of Lactococcus lactis subsp. diacitilactis S50. Appl Environ
Microbiol 57:1835–1837.
25. Holo H, Nes IF. 1989. High-frequency transformation, by electropora-
tion, of Lactococcus lactis subsp. cremoris grown with glycine in osmotically
stabilized media. Appl Environ Microbiol 55:3119 –3123.
26. Uzelac G, Miljkovic M, Lozo J, Radulovic Z, Tosic N, Kojic M. 2015.
Expression of bacteriocin LsbB is dependent on a transcription termina-
tor. Microbiol Res 179:45–53. http://dx.doi.org/10.1016/j.micres.2015.06
.011.
27. O’Neill AJ, Miller K, Oliva B, Chopra I. 2004. Comparison of assays for
detection of agents causing membrane damage in Staphylococcus aureus. J
Antimicrob Chemother 54:1127–1129. http://dx.doi.org/10.1093/jac
/dkh476.
28. Vukotic G, Mirkovic N, Jovcic B, Miljkovic M, Strahinic I, Fira D,
Radulovic Z, Kojic M. 2015. Proteinase PrtP impairs lactococcin LcnB
activity in Lactococcus lactis BGMN1-501: new insights into bacteriocin
regulation. Front Microbiol 6:92. http://dx.doi.org/10.3389/fmicb.2015
.00092.
29. Miller JM. 1972. Experiments in molecular genetics. Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY.
30. Attri P, Jodha D, Singh J, Dhanda S. 2012. An improved protocol for
rapid extraction of membrane enzymes from Gram positive bacteria. Anal
Methods 4:2574 –2577. http://dx.doi.org/10.1039/c2ay05931b.
31. Oppegård C, Rogne P, Kristiansen PE, Nissen-Meyer J. 2010. Structure
analysis of the two-peptide bacteriocin lactococcin G by introducing D-
amino acid residues. Microbiology 156:1883–1889. http://dx.doi.org/10
.1099/mic.0.038430-0.
32. Braine T. 2011. Race against time to develop new antibiotics. Bull World
Health Organ 89:88 – 89. http://dx.doi.org/10.2471/BLT.11.030211.
33. Gebhart G, Lok S, Clare S, Tomas M, Stares M, Scholl D, Donskey C,
Lawley TD, Govoni GR. 2015. A modified R-type bacteriocin specifically
targeting Clostridium difficile prevents colonization of mice without af-
fecting gut microbiota diversity. mBio 6(2):e02368-14. http://dx.doi.org
/10.1128/mBio.02368-14.
34. O’Shea EF, O’Connor PM, O’Sullivan O, Cotter PD, Ross RP, Hill C.
2013. Bactofencin A, a new type of cationic bacteriocin with unusual im-
munity. mBio 4(6):e00498-13. http://dx.doi.org/10.1128/mBio.00498-13.
35. Van Kraaij C, Breukink E, Rollema HS, Siezen RJ, Demel RA, De Kruijff
B, Kuipers OP. 1997. Influence of charge differences in the C-terminal part of
nisin on antimicrobial activity and signaling capacity. Eur J Biochem 247:
114–120. http://dx.doi.org/10.1111/j.1432-1033.1997.00114.x.
36. Quadri LE, Yan LZ, Stiles ME, Vederas JC. 1997. Effect of amino acid
substitutions on the activity of carnobacteriocin B2. Overproduction of
the antimicrobial peptide, its engineered variants, and its precursor in
Escherichia coli. J Biol Chem 272:3384 –3388.
37. Kazazic M, Nissen-Meyer J, Fimland G. 2002. Mutational analysis of the
role of charged residues in target-cell binding, potency and specificity of
the pediocin-like bacteriocin sakacin P. Microbiology 148:2019 –2027.
http://dx.doi.org/10.1099/00221287-148-7-2019.
38. Haugen HS, Kristiansen PE, Fimland G, Nissen-Meyer J. 2008. Muta-
tional analysis of the class IIa bacteriocin curvacin A and its orientation in
target cell membranes. Appl Environ Microbiol 74:6766 – 6773. http://dx
.doi.org/10.1128/AEM.01068-08.
39. Haugen HS, Fimland G, Nissen-Meyer J. 2011. Mutational analysis of
residues in the helical region of the class IIa bacteriocin pediocin PA-1.
Appl Environ Microbiol 77:1966 –1972. http://dx.doi.org/10.1128/AEM
.02488-10.
40. Plat A, Kluskens LD, Kuipers A, Rink R, Moll GN. 2011. Requirements
of the engineered leader peptide of nisin for inducing modification, ex-
port, and cleavage. Appl Environ Microbiol 77:604 – 611. http://dx.doi.org
/10.1128/AEM.01503-10.
41. Gasson MJ. 1983. Plasmid complements of Streptococcus lactis NCDO 712
and other lactic streptococci after protoplast-induced curing. J Bacteriol
154:1–9.
42. Valenzuela AS, ben Omar N, Abriouel H, López RL, Veljovic K,
Canamero MM, Kojic M, Topisirovic L, Gálvez A. 2009. Virulence
factors, antibiotic resistance, and bacteriocins in enterococci from artisan
foods of animal origin. Food Control 20:381–385. http://dx.doi.org/10
.1016/j.foodcont.2008.06.004.
43. Hanahan D. 1983. Studies on transformation of Escherichia coli with
plasmids. J Mol Biol 166:557–580. http://dx.doi.org/10.1016/S0022
-2836(83)80284-8.
44. Law J, Buist G, Haandrikman A, Kok J, Venema G, Leenhouts K. 1995.
A system to generate chromosomal mutations in Lactococcus lactis which
allows fast analysis of targeted genes. J Bacteriol 177:7011–7018.
45. Kojic M, Jovcic B, Strahinic I, Begovic J, Lozo J, Veljovic K, Topisirovic
L. 2011. Cloning and expression of a novel lactococcal aggregation factor
from Lactococcus lactis subsp. lactis BGKP1. BMC Microbiol 11:265–274.
http://dx.doi.org/10.1186/1471-2180-11-265.
Miljkovic et al.
5374 aem.asm.org September 2016 Volume 82 Number 17Applied and Environmental Microbiology
 on D
ecem
ber 12, 2020 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
